More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis.
نویسنده
چکیده
Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019.
منابع مشابه
New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
The development of effective and well-tolerated biologic therapies has advanced the management of psoriasis by enabling clinicians to treat underlying disease mechanisms. Biologics approved for the treatment of moderate-to-severe psoriasis include three tumor necrosis factor alpha inhibitors and an interleukin-12/interleukin-23 inhibitor. The establishment of the immunological basis of psoriasi...
متن کاملPustular psoriasis: pathophysiology and current treatment perspectives
Psoriasis vulgaris is a chronic inflammatory disease that classically affects skin and joints and is associated with numerous comorbidities. There are several clinical subtypes of psoriasis including the uncommon pustular variants, which are subdivided into generalized and localized forms. Generalized forms of pustular psoriasis include acute generalized pustular psoriasis, pustular psoriasis o...
متن کاملAlefacept treatment for chronic plaque psoriasis.
Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. These agents provide therapeutic alternatives to traditional topical and systemic therapies. Alefacept, the first such biologic agent, was approved by the US FDA in January 2003 for the treatment of chronic plaque psoriasis. This review will discuss data from clinical trials that have prov...
متن کاملRecapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
ADA: antidrug antibodies DLQI: Dermatology Life Quality Index PASI: Psoriasis Area and Severity Index INTRODUCTION Etanercept, adalimumab, infliximab, and ustekinumab are all biologic therapies licensed for the treatment of chronic plaque psoriasis in the United Kingdom. Although these therapies have advanced the treatment of psoriasis, they can lose effectiveness with time. Three studies looke...
متن کاملA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
• Interleukin (IL)-23 and IL-17 play an important role in the development of psoriasis. • Many of the new biologic drugs targeting IL-23 and IL-17 have been shown to be both safe and effective in treating moderate-to-severe plaque psoriasis. Long-term safety data still need to be established. • These drugs are more selective with inhibition of " downstream " targets in the immunopathogenesis of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 41 6 شماره
صفحات -
تاریخ انتشار 2016